Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-3373 versus adalimumab in moderate to severe rheumatoid arthritis
2018-003053-21Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ABBV-3373 in rheumatoid arthritis (RA) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Change in DAS28-CRP at Week 12. Started Apr 2019; status: completed.
02
Drugs
ABBV-3373
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2018-003053-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003053-21.